Please assess the completion status of the following clinical trial:

Trial Title: Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman within 48 h post partum~* Hemoglobin level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl~* Able to read and understand the Norwegian language~* Signed informed consent~Exclusion Criteria:~* Anemia not attributable to iron deficiency~* Contraindications for any of the study drugs~* Treatment with drugs, dietary supplements or natural remedies containing iron~* Clinically significant condition which in the opinion of the investigator should disqualify the patient from the study~* Assessed as requiring blood transfusion(s)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Peroral iron - ferrous sulfate tablets (Type: ACTIVE_COMPARATOR): Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
- Ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.

Based on this trial design, predict the completion outcome and termination type (if applicable).